Advertisement
Advertisement
CGON
CG Oncology, Inc. Common stock
73.52
USDSponsored
+4.20
+6.06%
Jul 27, 15:59 UTC -4
Closed
After-Market
74.45
+0.94
+1.27%
CGON Earnings Reports
Positive Surprise Ratio
CGON beat 4 of 10 last estimates.
40%
Next Report
Date of Next Report
Aug 07, 2026
Estimate for Q2 26 (Revenue/ EPS)
$340.91K
/-$0.67
Implied change from Q1 26 (Revenue/ EPS)
-68.52%
/-5.63%
Implied change from Q2 25 (Revenue/ EPS)
--
/+24.07%
CG Oncology, Inc. Common stock earnings per share and revenue
On May 08, 2026, CGON reported earnings of -0.71 USD per share (EPS) for Q1 26, missing the estimate of -0.57 USD, resulting in a -23.03% surprise. Revenue reached 1.08 million, compared to an expected 503.04 thousand, with a 115.29% difference. The market reacted with a +0.64% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -0.67 USD, with revenue projected to reach 340.91 thousand USD, implying an decrease of -5.63% EPS, and decrease of -68.52% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
GeoVax Labs, Inc. New
Report Date
Jul 27, 2026 For Q2 26
Estimate
-$2.93
Actual
-$0.97
Surprise
+66.98%
FAQ
What were CG Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, CG Oncology, Inc. Common stock reported EPS of -$0.71, missing estimates by -23.03%, and revenue of $1.08M, 115.29% above expectations.
How did the market react to CG Oncology, Inc. Common stock's Q1 2026 earnings?
The stock price moved up 0.64%, changed from $69.18 before the earnings release to $69.62 the day after.
When is CG Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for Aug 07, 2026.
What are the forecasts for CG Oncology, Inc. Common stock's next earnings report?
Based on 12
analysts, CG Oncology, Inc. Common stock is expected to report EPS of -$0.67 and revenue of $340.91K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement